NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $18.21 +1.06 (+6.18%) Closing price 04:00 PM EasternExtended Trading$17.02 -1.19 (-6.56%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rigel Pharmaceuticals Stock (NASDAQ:RIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rigel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.15▼$18.3050-Day Range$17.15▼$24.3952-Week Range$7.48▼$29.82Volume204,696 shsAverage Volume207,730 shsMarket Capitalization$325.29 millionP/E Ratio130.08Dividend YieldN/APrice Target$36.80Consensus RatingHold Company OverviewRigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More… Remove Ads Rigel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreRIGL MarketRank™: Rigel Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 442nd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Rigel Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth377.27% Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is 128.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is 128.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.61.Read more about Rigel Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.03% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.03% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.90 News SentimentRigel Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $190,644.00 in company stock.Percentage Held by InsidersOnly 9.04% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Stock News HeadlinesRigel Pharmaceuticals resolves patent litigation related to TavalisseMarch 28, 2025 | markets.businessinsider.comRigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent LitigationMarch 27, 2025 | prnewswire.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings AreMarch 15, 2025 | finance.yahoo.comRigel Pharmaceuticals appoints new board memberMarch 12, 2025 | uk.investing.comRigel Pharmaceuticals Appoints Dr. Frohlich to BoardMarch 10, 2025 | tipranks.comRigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats ExpectationsMarch 10, 2025 | finance.yahoo.comRigel Appoints Mark W. Frohlich, M.D. to Board of DirectorsMarch 10, 2025 | finance.yahoo.comSee More Headlines RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $16.82 at the start of the year. Since then, RIGL shares have increased by 6.8% and is now trading at $17.96. View the best growth stocks for 2025 here. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings results on Tuesday, March, 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.50. The biotechnology company had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative trailing twelve-month return on equity of 14.80%. When did Rigel Pharmaceuticals' stock split? Shares of Rigel Pharmaceuticals reverse split on Thursday, June 27th 2024. The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings3/04/2025Today4/02/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees160Year Founded1996Price Target and Rating Average Stock Price Target$36.80 High Stock Price Target$57.00 Low Stock Price Target$23.00 Potential Upside/Downside+114.6%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.94 Trailing P/E Ratio122.51 Forward P/E Ratio77.95 P/E GrowthN/ANet Income$-25,090,000.00 Net Margins2.46% Pretax Margin2.46% Return on Equity-14.80% Return on Assets3.03% Debt Debt-to-Equity RatioN/A Current Ratio1.96 Quick Ratio1.87 Sales & Book Value Annual Sales$179.28 million Price / Sales1.71 Cash FlowN/A Price / Cash FlowN/A Book Value($1.64) per share Price / Book-10.46Miscellaneous Outstanding Shares17,863,000Free Float16,023,000Market Cap$306.35 million OptionableOptionable Beta1.35 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RIGL) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.